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Abstract
Background: Adverse drug reactions (ADR's) could be expected more frequently in pregnant
women. This study was performed in order to identify ADR's to tocolytic drugs in hospitalised
pregnant women.
Methods: A prospective cohort study was performed in two General Hospitals of the Instituto
Mexicano del Seguro Social (IMSS) in Mexico City. Two hundred and seven women undergoing labor,
premature labor, threatened abortion or suffering any obstetric related disease were included.
Drug prescription and signs and symptoms of any potential ADR were registered daily during the
hospital stay. Any potential ADR to tocolytic drugs was evaluated and classified by three of the
authors using the Kramer's algorithm.
Results: Of the 207 patients, an ADR was positively classified in 25 cases (12.1%, CI95% 8.1 to
17.5%). All ADR's were classified as minor reactions. Grouping patients with diagnosis of
threatened abortion, premature labor or under labor (n= 114), 24 ADR's were related to
terbutaline, accounting for a rate of 21.1 ADR's per 100 obstetric patients. Obstetric patients
suffering an ADR were older than obstetric patients without any ADR. However, the former
received less drugs/day ×  patient-1 and had a shorter hospital stay (p < 0.05) whereas the dose of
terbutaline was similar between the two groups. Terbutaline inhibited uterine motility in women
with and without any ADR at a similar rate, 70 and 76% respectively (x2 = 0.07; p = 0.8).
Conclusion: Terbutaline, used as a tocolytic drug, was related to a high frequency of minor ADRs
and to a high rate of effcicacy.
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Background
The ADR's are considered as a major public health prob-
lem [1]. Being the fourth cause of general deaths [2], the
ADR's are costly and represent a significant rate of hospital
admissions [3,4]. Furthermore, the number of drugs avail-
able for prescription in the clinical setting is increasing
every day. It is therefore important to acquire, interpret
and report all ADR's identified with any drug [2]. Further-
more, pharmacovigilance in special populations, e.g.
pregnancy women, could be useful to identify unexpected
responses probably expressing unusual pharmacokinetic
profiles as a result of their particular physiological state
[5,6].
Multiple methods have been used for pharmacovigilance,
and despite spontaneous reporting is the simplest one, it
has been of low efficacy in Mexican medical practice [7].
Furthermore, in Latin-America only a limited number of
drug utilization studies done in order to report any ADR
during clinical practice are available. In Mexico, the pop-
ulation is growing at a yearly rate of 1.85, representing ap-
proximately more than 2 millions of newborns every year
[8]. The IMSS, one of the two social health systems avail-
able in Mexico, is responsible to attend approximately
60% of the Mexican citizens and also a considerable rate
of deliveries [9], resulting into a major source of informa-
tion on drugs utilization. The present study was per-
formed in order to identify any ADR to tocolytic drugs in
a prospective cohort of hospitalised pregnant women re-
quiring medical attention at the IMSS.
Materials and Methods
After approval by the National Research Committee of the
IMSS, the study was performed at the Gynecology and Ob-
stetric units of two secondary-care general hospitals. Selec-
tion of these hospitals was based on their similar
characteristics of medical care while they had a different
geographic distribution, one at the north and other at the
south of Mexico City. A minimal sample size of 148 pa-
tients was estimated using previous studies on ADR's with
an expected frequency of ≥  2.5% and a significant level of
5% [10,11]. During the study period, 207 women in la-
bor, premature labor, threatened abortion or suffering any
obstetrical related disease referred to any of the two hos-
pitals over a 4-month period were included into the co-
hort, and data were obtained during their hospital stay.
Data collection
General information including age (yr.), level of educa-
tion (according to the basic Mexican scholar system, pa-
tients were grouped into ≤  6 and >6 years of scholar level),
diagnosis (cesarean section, labor, premature labor,
threatened abortion, or post-cesarean complications),
and hospital stay (days) were obtained. Drugs and dose
administrated were obtained from the medical and nurs-
ery records. Patients were questioned daily, in relation to
the presence or not, of symptoms relating to drug admin-
istration. Nurses trained for purpose of the study collected
data and an Obstetrician confirmed clinical information.
Causality assessment
For identifying any ADR, the Kramer's algorithm was used
[12–14]. This system was previously translated into Span-
ish and successfully used in pediatric patients [15]. Briefly,
the algorithm contains 56 questions grouped in six deci-
sion-making axes, and it evaluates previous experiences
with any drug, potential etiologies of the ADR, a tempo-
rary relationship between drug administration and the
presence of the ADR, the possibility of an overdoses, and
any re-challenge with the suspected drug. Each axe is grad-
ed and a total score is obtained to classify the reaction as
improbable (<0), possible (0,+1,+2,+3), probable (+4,+5)
and definitive (+6,+7). For patients receiving more than
one drug, each drug was evaluated by means of the algo-
rithm. Any possibility of drugs interaction was evaluated
by means of the Drug interaction program (The Medical
Letter, Inc., New Rochelle, NY, USA). An ADR was posi-
tively qualified if two or all the evaluators qualified a sus-
pected ADR as either probable or definitive. The file of
each patient was reviewed independently by three of the
authors trained to use the algorithm (AA Nava-Ocampo,
JA Palma-Aguirre and H Sumano-López). Inter-observer
agreement among the three evaluators in relation to the
scores given to every potential ADR was computed by
means of a Kappa analysis at a p < 0.05 level [16,17]. Fi-
nally, severity of each ADR was scored according to Capel-
lá and Laporte into mortal, severe (any life-threatening
reaction), moderate (any reaction requiring hospitaliza-
tion or requiring urgent atention), or mild [18].
Statistical analysis
Data from all patients were summarized by using descrip-
tive statistics. Patients were further goruped into patients
suffering or not any ADR. Except for vitamins, all drugs re-
ceived by patients were presented as only one active prin-
ciple. We therefore counted all drugs daily received by
each patient and obtained a mean value. Results were then
summarized and a final mean value and SD of number of
drugs/day ×  patient-1 was obtained. The unpaired Student
t test was used to compare age and drugs/day ×  patient-1
between patients suffering or not an ADR. The dose of
terbutaline was also compared between the two groups by
means of the unpaired Student t test. The Fishers' exact
chi-square test was used to evaluate differences in diagno-
sis and type of drug used for uterine activity inhibition
(terbutaline, indometacine, or none) between groups. The
significant level for all statistical analyses was fixed at a p
< 0.05. When used, the parametric 95% confidence inter-
val for the difference was computed.BMC Pregnancy and Childbirth 2002, 2 http://www.biomedcentral.com/1471-2393/2/3
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Software
Data were collected in a predesigned Microsoft® Excel 97
form. For statistical anaylsis, we used the Epi-lnfo® 6 v.
6.04d (The Center for Disease Control and Prevention, At-
lanta, Georgia, USA).
Results
Demographic data were summarized in Table 1. Patients
were young people, most of them have the basic educa-
tion level, and patients undergoing cesarean section was
the the major clinical condition.
In relation to the ADR's, agreeement among the reviewers
for classification of each ADR was satisfactory (Kappa >
0.92). Of the 207 patients included in the cohort, 28 pre-
sented any suspected ADR, being 25 positively classified
(12.1%, 95%CI 8.1 to 17.5%). Grouping patients with di-
agnosis of threatened abortion, premature labor or under
labor (n= 114), 24 ADR's were related to terbutaline, ac-
counting for a rate of 21.1 ADR's per 100 obstetric pa-
tients.
Patients suffering an ADR were slightly but significantly
older than those wihout any ADR (Table 2). They also
were attended mainly for premature labor, have a lower
hospital stay, and they were mainly receiving terbutaline.
However, the dose of terbutaline was similar between the
two groups. The tocolytic therapy with terbutaline inhib-
ited uterine motility in women with with and without any
ADR in a similar rate, 70 and 76% (x2 0.07; p = 0.8), re-
spectively. Of the 24 patients suffering an ADR to terbuta-
line, tremor was present in all patients, dizziness in seven,
confusion in six, depression in five, adynamia in three, as-
tenia in other three and headache also in three patients,
and loss of equilibrium in one, irritability in one, and pal-
pitations and aggressiveness in another patient. The only
patient suffering an ADR to indomethacin referred ab-
dominal discomform. All ADR's were classified as minor
reactions, and according with the obstetricians did not
merit to prolong the hospital stay, any additional treat-
ment or drug discontinuation, and no fetal complications
was reported by the patient or at the maternal records dur-
ing the hospital stay.
Table 1: Characteristics of the population
n = 207
AGE (years)* 27.2 ± 5.2
SCOLARITY
≤  6 yr 36(17.4)
>6 yr 171 (82.6)
DIAGNOSTICS
Threatened abortion 27(13.1)
Premature labor 48 (23.2)
Labor 39(18.8)
Cesarean section 75 (36.2)
Post-cesarean complications 18(8.7)
HOSPITAL STAY (days)* 3.1 ± 0.7
* data expressed as mean ± sd
Table 2: Characteristics of patients with diagnosis of threatened abortion, premature labor or labor in relation to the presence or not 
of any ADR.
With ADR (n = 25) Without ADR (n = 89) Significant level
Age (yr., mean ± SD) 28.8 ± 5.9 25.6 ± 6.0 p = 0.02
DIAGNOSIS
Threatened abortion 4(16%) 23 (25.8%)
Premature labor 20 (80%) 28(31.5%) <0.001
Labor 1 (4%) 38 (42.7%)
HOSPITAL STAY (days)
≤  3 20 (80%) 45 (50.6%) p= 0.016
>3 5 (20%) 44 (49.4%)
DRUGS/DAY ×  PATIENT-1
Mean ± SD 3.3 ± 1.3 4.4 ± 2.2 p = 0.02
UTERINE INHIBITOR
a) Terbutaline 24 (96%) 19(21.3%)
b) Indomethacin 1 (4%) 35 (40.4%) p < 0.001
c) None - 34 (38.3%)
TERBUTALINE DOSE (mg/day)
Mean ± SD 13.0 ± 3.5 14.5 ± 2.2 p > 0.05
Range 5–15 5–15BMC Pregnancy and Childbirth 2002, 2 http://www.biomedcentral.com/1471-2393/2/3
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Discussion
Kramer et al., created an algorithm to identify and qualify
any ADR without any drug assay [12–14]. However, some
problems have emerged with its use. It needs to be trans-
lated and adapted for using in different countries, as it
happened to us. The algorithm is extensive, and therefore
time-consuming. It requires multiple specific information
that was collected due to the prospective nature of the
present study. Some data, however, could not be available
in the clinical file for a retrospective evaluation.
Despite the Council of the International Organization of
Medical Sciences has provided definitions and basic re-
quirements for the proper use of ADR terminology [19], a
diagnosis is often difficult to establish due to the presence
of clinical conditions or prescription of two or more
drugs. Casuality assessment for ADR's is therefore often
difficult in the clinical setting [20]. Comparisons among
the reported ADR's frequencies are also problematic due
to the differences observed among the studies, including
the population (e.g. pediatric, adults or old patients), gen-
der, set of the study (e.g. emergency rooms or hospitalized
patients), and method of measurement (e.g. therapeutic
drug monitoring, spontaneous reports) [4,10,11,21–28] .
The frequency of 12.1% of ADR's reported in the current
study was lower than the 33.3% reported for all admis-
sions at an Indian hospital [29], and than 28.2% reported
at a Universitary hospital [11]. However, it resulted higher
than 2.4 to 3.7% of ADR's observed in other studies for
hospitalized patients [4,10]. Differences could be ex-
plained by the fact that obstetric patients do receive a less-
er amount or less agressive theraphy than patients
attended e.g. at internal medical wards.
We studied women patients requiring hospital attention
for non-accidental causes, and despite a high incidence of
ADR's was identified in patients receiving terbutaline for
premature labor and threatened abortion, mortality was
not present. Terbutaline is worldwide formerly approved
for the treatment of asthma. As it was recently reviewed by
Lam et al. [30], in the United States the off-label utility of
terbutaline as a tocolytic agent has been known by clini-
cians for more than 20 years, estimating that at least
260,000 women are yearly receiving terbutaline during
pregnancy, being the most popular prescribed β -mimetic
for tocolysis in the USA. In Mexico, it is also extensively
used in the obstetric wards provably favored by the fact
that other therapuetic options as ritodrine did never arrive
to our country. In fact, ritodrine was removed from the
marked in the United States [30].
Terbutaline is clearly an effective inhibitor of uterine activ-
ity [31,32], and its ADR's are abated with discontinuing
treatment only. In our study, no differences in dose of
terbutaline were detected between patients suffering or
not an ADR. Although efficacy was not our goal, the uter-
ine inhibitor effects of terbutaline resulted in a high rate
of patients. The study was performed during a period of 4
months and we did not observe any patient re-entering
into the hospital because of the presence of a new episode
of uterine activity. Whether the patients underwent anoth-
er period of uterine activity and received medical care in
another hospital or successfully completed the pregnancy
period, cannot be clarified in our study. Also, the fetal and
maternal long-term morbidity was unknown. Obstetri-
cian service is the main request of medical care in Mexican
hospitals, and births have been 31.2% of total hospital
discharges, being 53.9% of total births registered in 1997
attended at the IMSS [9]. A careful selection of pregnant
women in order to avoid a dangerous impact to both or
either the mother and the fetus due to the production of
palpitations counterbalancing the benefits between its use
for managing a threatened abortion or a premature labor
and costs of minor ADR's, must be mandatory. Further-
more, the small range of current options to be used as to-
colytics should stimulate this area in order to identify
drugs with lesser production of side effects. In fact, terbu-
taline could not only be undangerous for the fetus but to
promote neonatal respiration and metabolic adaptation
after elective cesarean section and to reduce the number of
fetal heart abnormalities [33,34].
In relation to indomethacin, this drug has proved safety
and efficacy to inhibit uterine contractions of premature
labor [35,36]. Uterine contractility at term and preterm re-
sults from an activation of myometrium through several
process varying from mechanical stimulation to a com-
plex cascade of endocrine processes [37]. Prostaglandinds
are important regulators of the labor process [38], and
therefore its manipulation has resulted into a direct effect
favoring or inhibiting uterine activity [39,40]. However, it
is well known the adverse effects of all nonsteroidal anti-
inflamatory drugs administered at the third trimester of
pregnancy [41–43], including constriction of the ductus
arteriosus, persistent fetal circulation, impairment of renal
function and bleeding. Furthermore, brain maldevelop-
ment and neurobehaviour deviations have been experi-
mentally demonstrated after neonatal exposure to
indomethacin [44]. Therefore, despite our results seem
likely to favour indomethacin administration because it
was better tolerated than terbutaline for tocolysis, the se-
rious adverse effects potentially produced in the fetus by
indomethacin make this drug a greatly dangerous option
for preterm labor management.
Additionally, incidence of preterm birth is greatly in-
creased among the socially disadvantaged women, proba-
bly explained by two major factors [45]. First, the presence
of chronic and acute social stressors which in turn are
translated into organc responses. Second, the presence ofBMC Pregnancy and Childbirth 2002, 2 http://www.biomedcentral.com/1471-2393/2/3
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a gene-environment interaction based on a highly preva-
lence mutation in the gene for methylentetrahydrofolate
reductase. Even more, maternal education level could de-
crease infant mortality rate by preventing preterm births
[46], without affecting fetal growth [47]. In the present
study, most patients have the basic education level, and
therefore if any effect was present this would be protector.
Finally, there is a need for a simple, efficient and low-cost
of ADR's reporting system covering a wide range of the
population receiving any drug. The spontaneous reports
probably satisfy these conditions and participation of
nurses in the design of strategies of recognizing any ADR
is undoubtedly necessary [48,49].
In conclusion, terbutaline was responsible of a high rate
of mild ADR's in women receiving this drug as a tocolytic
agent. However, the lack of well recognized options
makes terbutaline the major tocolytic drug currently avail-
able.
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